Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effects of a Combination of Bifidobacterium Longum Subsp. Longum Strains on Stress and Related Health Outcomes in Young Adult

10 november 2026 uppdaterad av: DiproBio (Shanghai) Co., Ltd.

Effect of Bifidobacterium Longum Subsp. Longum Combination Intervention on Stress Status and Related Health Outcomes: A Randomized, Double-Blind, Placebo-Controlled Clinical Study

This study is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to evaluate the effects of a combination of Bifidobacterium longum subsp. longum strains on stress-related health outcomes in adults. The study plans to enroll 126 adults experiencing stress-related problems, who will be randomly assigned in equal proportions to either the probiotic group or the placebo group and will receive the assigned intervention for 8 weeks. Participants will complete the scheduled study visits and assessments.

The study will systematically evaluate the principal health concerns of young adults experiencing high levels of stress through multiple approaches, including subjective questionnaire assessments, biological sample testing, and gut microbiome analysis. The main assessments will include a comparison of changes in stress status before and after the intervention between the probiotic and placebo groups using validated psychological assessment instruments. The effects of the intervention on sleep quality, quality of life, and related emotional states will also be evaluated. Sleep quality and quality of life will be assessed using validated assessment instruments.

To further investigate the potential biological mechanisms, stool samples will be collected from participants for gut microbiome metagenomic analysis to characterize changes in microbial composition and functional features. Laboratory-based assays will also be used to measure stress-, immune-, and inflammation-related biomarkers. This study is expected to provide preliminary evidence supporting the clinical application of microbiota-targeted interventions based on modulation of the gut-brain axis in populations experiencing high levels of stress.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

126

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Gansu
      • Lanzhou, Gansu, Kina, 730030
        • Northwest Minzu University
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Adults aged 18-65 years.
  2. Perceived Stress Scale-10 (PSS-10) score ≥ 14.
  3. Voluntary participation in the study and provision of written informed consent before any study procedures begin.

Exclusion Criteria:

  1. Use of probiotic supplements or probiotic-containing products within 4 weeks before enrollment.
  2. Use of antibiotics or systemic glucocorticoids within 4 weeks before enrollment.
  3. Current or previous diagnosis of psychiatric disorders (e.g., schizophrenia or major depressive disorder), epilepsy, major endocrine disorders, active inflammatory bowel disease or other severe gastrointestinal disorders, or severe sleep disturbances requiring treatment adjustment.
  4. Use of medications or dietary supplements that may affect the gut-brain axis, sleep, mood, or stress status assessment within 4 weeks before enrollment, including but not limited to sedative-hypnotics, anxiolytics, antidepressants, antipsychotics, mood stabilizers, and supplements with sleep-inducing, sedative, or stress-relieving effects (e.g., magnesium-containing supplements).
  5. Pregnant or breastfeeding women.
  6. Known allergy to the study product or any of its components.
  7. Smoking or alcohol consumption on the day of the study visit or within 48 hours before the visit.
  8. Participation in other clinical intervention studies involving drugs, dietary supplements, probiotics, or prebiotics within the past 3 months.
  9. Insufficient compliance, as judged by the investigator, to complete sample collection or study-related documentation as required by the study protocol.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Probiotic group

Participants receive Bifidobacterium longum subspecies combination formulation.

Participants receive an oral probiotic combination formulation according to the study protocol for the duration of the intervention.

Placebo-jämförare: Placebo group

Participants receive a matching placebo formulation.

Participants receive a matching placebo formulation according to the same administration schedule as the probiotic intervention.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Depression Anxiety Stress Scales-42 (DASS-42) Stress Subscale Score
Tidsram: Baseline, Week 4, Week 8

Stress levels will be assessed using the Stress subscale of the 42-item Depression Anxiety Stress Scales (DASS-42). The subscale consists of 14 items, each scored from 0 to 3. The total Stress subscale score ranges from 0 to 42, with higher scores indicating greater stress severity. Raw scores will be reported at each assessment time point.

Baseline, Week 4, Week 8

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pittsburgh Sleep Quality Index (PSQI) Global Score
Tidsram: Baseline, Week 4, Week 8

Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The global score is calculated by summing seven component scores, each ranging from 0 to 3. The total global score ranges from 0 to 21, with higher scores indicating poorer sleep quality. Raw PSQI global scores will be reported at each assessment time point.

Baseline, Week 4, Week 8
WHOQOL-BREF Physical Health Domain Score
Tidsram: Baseline, Week 4, Week 8

Quality of life in the physical health domain will be assessed using the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire. Domain scores will be transformed to a scale ranging from 0 to 100, with higher scores indicating better quality of life in the corresponding domain. Raw transformed domain scores will be reported at each assessment time point.

Baseline, Week 4, Week 8
Relative Abundance of Prespecified Gut Microbial Taxa
Tidsram: Baseline, Week 4, Week 8

The relative abundance of prespecified gut microbial taxa will be assessed using shotgun metagenomic sequencing of fecal samples. Relative abundance will be expressed as a percentage of the total taxonomic abundance assigned to the selected taxa at each assessment time point.

Baseline, Week 4, Week 8
Gut stress and immune biomarkers
Tidsram: Baseline, Week 4, Week 8
Baseline, Week 4, Week 8

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

9 november 2026

Primärt slutförande (Beräknad)

30 juni 2027

Avslutad studie (Beräknad)

30 juni 2027

Studieregistreringsdatum

Först inskickad

3 november 2026

Först inskickad som uppfyllde QC-kriterierna

10 november 2026

Första postat (Faktisk)

16 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • XBMU-YX-20260038

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera